Download PDF
Semin Thromb Hemost 2025; 51(05): 578-593
DOI: 10.1055/a-2528-5425
Review Article

Anti-platelet Factor 4 Antibody-Mediated Disorders: An Updated Narrative Review

Authors

  • Angela Napolitano

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  • Luca Spiezia 

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  • Marta Biolo

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  • Claudia Maria Radu

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  • Serena Toffanin

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  • Elena Campello

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy

  • Paolo Simioni

    1   First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
Further Information
   Permissions and Reprints
Preview

Abstract

Anti-platelet factor 4 (PF4) antibody-mediated disorders are a heterogeneous group of diseases characterized by the presence of highly pathogenic immunoglobulins G directed against PF4 and/or PF4/heparin complexes. These antibodies are able to activate platelets, neutrophils, and monocytes, thus resulting in thrombocytopenia and a hypercoagulable state. Five different forms of anti-PF4 antibody-mediated disorders have been identified: (1) classic heparin-induced thrombocytopenia (HIT) mediated by heparin and certain polyanionic drugs; (2) autoimmune HIT characterized by the presence of anti-PFA/polyanion antibodies that can strongly activate platelets even in the absence of heparin; (3) spontaneous HIT characterized by thrombocytopenia and thrombosis without proximate exposure to heparin, with two subtypes: (a) post-total knee arthroplasty and cardiac surgery using cardiopulmonary bypass or extracorporeal membrane oxygenation and (b) postinfections; (4) vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by thrombocytopenia, arterial and venous thrombosis, or secondary hemorrhage after receiving adenoviral vector vaccines for coronavirus disease 2019; (5) VITT-like disorders triggered by adenoviral infections. Although extremely rare and largely unknown, there has been growing interest in the VITT syndrome in recent years due to its clinical relevance. Timely detection of these antibodies is crucial for the diagnosis and treatment of anti-PF4 antibody-mediated disorders, via anti-PF4 antibody immunoassays using several antibody capture systems (e.g., enzyme-linked immunosorbent assay-based, particle gel, turbidimetry) and functional assays (e.g., serotonin release assay or heparin-induced platelet activation). We aimed to present the latest on laboratory findings, clinical characteristics, and therapeutic approaches for anti-PF4 antibody-mediated disorders.

Keywords

anti-PF4 antibody-mediated disorders - heparin-induced thrombocytopenia - VITT

Authors' Contributions

A.N. and L.S.: writing—original draft; M.B.: writing—“laboratory findings;” C.M.R. and S.T.: lab experiments—[Fig. 5]; E.C. and P.S.: writing—review and editing.




Publication History

Accepted Manuscript online:
30 January 2025

Article published online:
19 February 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA